



3 June 2008  
Australian Securities Exchange

### **QRXPHERMA LAUNCHES ADR PROGRAM**

QRxPharma (ASX: QRX) is pleased to announce that it has initiated a Level 1 American Depositary Receipt (ADR) Program.

The ADR program will enable QRxPharma shares to be more accessible to US institutions and private investors, including those permitted to buy only US-based securities.

JP Morgan Chase Bank will operate the program and will act as the Depositary Bank.

In accordance with normal ADR practice, shares are consolidated into larger value parcels. In QRxPharma's case each ADR will represent 5 ordinary QRxPharma shares.

This initiative forms part of QRxPharma's strategy to expand its US investor base, provide greater access to capital markets and increase the liquidity of its stock.

####

For more information please contact:

John Holaday  
Managing Director and Chief Executive Officer  
Tel: +1 301 908 3086  
Email: [john.holaday@qrxpharma.com](mailto:john.holaday@qrxpharma.com)

Chris J Campbell  
Chief Financial Officer and Company Secretary  
Tel: +61 2 9492 8021  
Email: [chris.campbell@qrxpharma.com](mailto:chris.campbell@qrxpharma.com)

#### **About QRxPharma**

QRxPharma (ASX: QRX) is a clinical-stage specialty pharmaceutical company focused on the development and commercialisation of new treatments for pain management and central nervous system (CNS) disorders. Based on a development strategy which focuses on enhancing and expanding the clinical utility of currently marketed compounds, the Company's product portfolio includes both late and early stage clinical drug candidates with the potential for reduced risk, abbreviated development paths, and improved patient outcomes. The company intends to directly commercialise its products in the US and seek strategic partnerships abroad. QRxPharma's lead compound, Q8003IR, successfully completed a Phase 3 study and met primary endpoints. The Company's preclinical and clinical pipeline includes other technologies in the fields of pain management, neurodegenerative disease and venomics. For more information: [www.QRxPharma.com](http://www.QRxPharma.com).